Lilly trial shows weight loss with experimental pill flattens over time

Eli Lilly's experimental oral GLP-1 drug, orforglipron, achieved a 12% body weight reduction plateauing at 72 weeks in its Phase 3 trial, a result less robust than Novo Nordisk's injectable Wegovy, which previously contributed to a 14% drop in Lilly's shares upon initial announcement. Despite this, the drug demonstrated clinically meaningful improvements in cardiovascular risk factors and inflammation, though it presented mild-to-moderate gastrointestinal side effects leading to a 10.3% dropout rate for high-dose patients. This full data release provides crucial insight into its competitive positioning within the rapidly expanding GLP-1 market.

Analysis

The full Phase 3 trial data for Eli Lilly's oral GLP-1 drug, orforglipron, confirms a weight loss of approximately 12% which plateaus at 72 weeks. This efficacy is less robust than that of Novo Nordisk's injectable Wegovy and also falls short of the nearly 15% reduction observed in orforglipron's own 36-week Phase 2 study, providing context for the 14% decline in Lilly's shares when top-line results were first announced. While the drug demonstrated clinically meaningful improvements in cardiovascular risk factors, including a 47.7% reduction in a key inflammation marker, its tolerability profile presents a significant hurdle. Gastrointestinal side effects were common, leading to a 10.3% patient dropout rate in the high-dose group, compared to just 2.6% for placebo. This high discontinuation rate, coupled with a 33.7% incidence of nausea, suggests potential challenges for patient adherence and real-world adoption. The negative sentiment score for Lilly (-0.5) versus the positive score for Novo Nordisk (+0.2) accurately reflects the market's interpretation: orforglipron is a viable oral option but its efficacy and tolerability trade-offs likely limit its ability to disrupt the market leaders.

Key Decisions for Investors

• Investors should moderate expectations for orforglipron's market penetration, as its 12% weight loss efficacy and 10.3% discontinuation rate due to side effects may position it as a second-line oral option rather than a direct competitor to high-efficacy injectables.
• The data provides a relative tailwind for Novo Nordisk, as orforglipron does not appear to pose the disruptive threat that a higher-efficacy, well-tolerated oral alternative would have, potentially solidifying the market-leading position of its injectable treatments.
• Monitor future commentary from Eli Lilly on its commercialization strategy and physician feedback regarding the gastrointestinal side effects, as real-world patient adherence will be the critical determinant of the drug's ultimate revenue potential.